Molecular Analysis for Combination Therapy Choice

EAY-191
ComboMATCH Registration Trial
Pi: James Ford

Genomic Data Reviewed and Treatment Trials Assignment Provided to Site

Other Arms to Open in the Near Future

Treatment trials

Previous Taxane Therapy

AKT Mutation

ECOG-ACRIN-EAY191-S3
Phase II Paclitaxel + Ipilimumab in Taxane-Refractory Participants w/ AKT-Altered Advanced Non-Breast Solid Tumors (A ComboMATCH Treatment Trial)
Pi: Ford Sponsor: ECOG-ACRIN

No Mutations

ECOG-ACRIN-EAY191-E4
Nilotinib & Paclitaxel in Patients w/ Prior Taxane-Treated Solid Tumors (A ComboMATCH Treatment Trial)
Pi: Ford Sponsor: ECOG-ACRIN

KEY

- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Enrollment on Hold
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu